William Blair Reaffirms Outperform Rating for Amedisys (NASDAQ:AMED)

William Blair reaffirmed their outperform rating on shares of Amedisys (NASDAQ:AMED) in a report issued on Tuesday, November 21st.

A number of other research firms have also recently weighed in on AMED. Oppenheimer restated a buy rating and issued a $60.00 price target on shares of Amedisys in a report on Friday, September 15th. Mizuho cut Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a research note on Wednesday, July 26th. BidaskClub cut Amedisys from a hold rating to a sell rating in a research note on Saturday, August 5th. Bank of America initiated coverage on Amedisys in a research report on Monday, August 21st. They set a neutral rating and a $55.00 price target on the stock. Finally, Royal Bank Of Canada reissued a hold rating on shares of Amedisys in a research report on Monday, October 23rd. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) traded up $1.57 during mid-day trading on Tuesday, reaching $54.53. 414,256 shares of the company traded hands, compared to its average volume of 331,957. Amedisys has a 12-month low of $39.95 and a 12-month high of $65.91. The firm has a market cap of $1,786.77, a P/E ratio of 25.19, a price-to-earnings-growth ratio of 1.27 and a beta of 0.70. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The firm had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. During the same quarter in the previous year, the company posted $0.36 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. sell-side analysts predict that Amedisys will post 2.23 EPS for the current year.

Several large investors have recently added to or reduced their stakes in AMED. Vanguard Group Inc. lifted its stake in Amedisys by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,386,046 shares of the health services provider’s stock worth $149,867,000 after acquiring an additional 16,368 shares in the last quarter. American Century Companies Inc. lifted its stake in Amedisys by 41.4% in the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after acquiring an additional 489,220 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Amedisys by 29.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after acquiring an additional 339,825 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Amedisys by 5.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,184,424 shares of the health services provider’s stock worth $66,280,000 after acquiring an additional 59,481 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Amedisys by 10.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock worth $47,375,000 after acquiring an additional 82,247 shares in the last quarter. Institutional investors and hedge funds own 94.32% of the company’s stock.

WARNING: “William Blair Reaffirms Outperform Rating for Amedisys (NASDAQ:AMED)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/07/amedisys-inc-amed-receives-new-coverage-from-analysts-at-william-blair.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply